

Andrea L Kwa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11941925/publications.pdf>

Version: 2024-02-01

34
papers

842
citations

687363

13
h-index

501196

28
g-index

34
all docs

34
docs citations

34
times ranked

1149
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the COVID-19 pandemic on a tertiary care public hospital in Singapore: resources and economic costs. <i>Journal of Hospital Infection</i> , 2022, 121, 1-8.	2.9	25
2	Distribution of serotypes and antibiotic resistance of invasive <i>Pseudomonas aeruginosa</i> in a multi-country collection. <i>BMC Microbiology</i> , 2022, 22, 13.	3.3	24
3	Predictors and Outcomes of Healthcare-Associated Infections Caused by Carbapenem-Nonsusceptible Enterobacterales: A Parallel Matched Case-Control Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 719421.	3.9	3
4	Estimating the excess bed days and economic burden of healthcare-associated infections in Singapore public acute-care hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-4.	1.8	4
5	Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1525-1537.	2.5	15
6	Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study. <i>Antibiotics</i> , 2020, 9, 451.	3.7	14
7	The impact of healthcare associated infections on mortality and length of stay in Singapore—A time-varying analysis. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1315-1320.	1.8	6
8	Elimination of Extracellular Adenosine Triphosphate for the Rapid Prediction of Quantitative Plate Counts in 24 h Time-Kill Studies against Carbapenem-Resistant Gram-Negative Bacteria. <i>Microorganisms</i> , 2020, 8, 1489.	3.6	1
9	The Diversity of Lipopolysaccharide (O) and Capsular Polysaccharide (K) Antigens of Invasive <i>Klebsiella pneumoniae</i> in a Multi-Country Collection. <i>Frontiers in Microbiology</i> , 2020, 11, 1249.	3.5	52
10	228. Impact of Early Alert to Antimicrobial Stewardship Interventions with the Prospective Audit and Feedback Strategy. <i>Open Forum Infectious Diseases</i> , 2018, 5, S98-S98.	0.9	0
11	187. Comparison of Active Versus Passive Strategies in Improving Compliance to Antimicrobial Stewardship Interventions. <i>Open Forum Infectious Diseases</i> , 2018, 5, S83-S83.	0.9	0
12	708. Incidence and Relatedness of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Infections in Previously Colonized or Infected Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S255-S255.	0.9	0
13	Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1591-1596.	2.7	6
14	Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	10
15	Prevalence of Healthcare-Associated Infections and Antimicrobial Use Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National Point Prevalence Survey. <i>Clinical Infectious Diseases</i> , 2017, 64, S61-S67.	5.8	97
16	Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant <i>Escherichia coli</i> in Time-Kill Studies and in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
17	From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB). <i>PLoS ONE</i> , 2016, 11, e0158740.	2.5	13
18	Outcomes on the Use of Daptomycin for the Treatment of Vancomycin-Resistant Enterococcal (VRE) Intra-abdominal Infections (IAI). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0

#	ARTICLE	IF	CITATIONS
19	Use of Ribavirin in Viral Respiratory Tract Infections in Singapore General Hospital. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
20	Implementing National Antimicrobial Stewardship Program (ASP): Our Singapore Story. Open Forum Infectious Diseases, 2016, 3, .	0.9	3
21	<i>In Vitro</i> Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B. Antimicrobial Agents and Chemotherapy, 2016, 60, 5238-5246.	3.2	14
22	A multidisciplinary antimicrobial stewardship programme safely decreases the duration of broad-spectrum antibiotic prescription in Singaporean adult renal patients. International Journal of Antimicrobial Agents, 2016, 47, 91-96.	2.5	15
23	Intravenous ceftaroline 200mg administered every 8h is safe and adequate for meticillin-resistant Staphylococcus aureus bloodstream infections in end-stage renal failure patients on haemodialysis: a case study. International Journal of Antimicrobial Agents, 2015, 46, 720-721.	2.5	2
24	Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae. Journal of Infection, 2015, 70, 309-311.	3.3	20
25	Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrobial Resistance and Infection Control, 2015, 4, 2.	4.1	42
26	Polymyxin B versus colistin: an update. Expert Review of Anti-Infective Therapy, 2015, 13, 1481-1497.	4.4	80
27	A procalcitonin-based guideline promotes shorter duration of antibiotic use safely in acute pancreatitis. Journal of Infection, 2014, 69, 412-415.	3.3	8
28	In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore. PLoS ONE, 2011, 6, e18485.	2.5	55
29	Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B. PLoS ONE, 2011, 6, e28177.	2.5	51
30	Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. Journal of Antimicrobial Chemotherapy, 2009, 63, 627-628.	3.0	6
31	In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore. Journal of Antibiotics, 2009, 62, 675-679.	2.0	27
32	Polymyxins: a review of the current status including recent developments. Annals of the Academy of Medicine, Singapore, 2008, 37, 870-83.	0.4	25
33	Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2005, 49, 3624-3630.	3.2	198
34	Rhodococcus equi Pneumonia in a Patient with Human Immunodeficiency Virus: Case Report and Review. Pharmacotherapy, 2001, 21, 998-1002.	2.6	12